Navigation Links
Malaria’s Invisibility Code Identifie

Research scholars belonging to the Howard Hughes Medical Institute (HHMI) have discovered how the malaria parasite, Plasmodium falciparum is able to turn on its cloaking genes, and pass the human immune system.// Even if the camouflage proteins of the parasite were to be detected by the immune system, the remaining parasites can still escape by switching disguises.

Malaria takes a toll of 2.7 million human lives annually, mostly in Africa. The survival of the parasite is based on its genetic machinery, according to the HHMI research. The gene's promoter which is a DNA sequence initiates the production of its protein, and also keeps under cover the other cloaking genes, according to researchers Brendan Crabb and Alan Cowman. The chief site of action is the promoter, according to them.

The PfEMP1 protein is used by the malaria parasites on the cells which they occupy. The immune system of human beings is evaded by the use of this surface protein. The protein is however incapable of protecting the parasite from immune cells which are on the patrol, making it necessary for the parasite to change its camouflage frequently.

Continuous exposure to malaria is required to gain immunity from it, and by and large children account for the largest number of casualties to the infection. The P. falciparum's 14 chromosomes are where the genes are generally found. The chromosome packaging regulates the var genes, according to the study. The DNA can be encased in chromosomes very securely by certain proteins. The genetic activity takes place at the very edge of the nucleus, wherein the chromosome ends surround the promoter which contain the silenced var genes. The art of cloning big DNA sequences had to be mastered by the scientists for this research.

The parasite’s var genes can be silenced by a promoter. The antigenic variation program has been infiltrated for the first time through this research, and this can also be utilized to find out how immunity from the disease is attained. The var gene machinery is being disassembled by the researchers with the object of identifying the proteins which activate and unpack the promoter region. The final object of the research is to identify new therapies which will counter the immune evasion strategies of the parasite.


'"/>




Related medicine news :

1. The heat is on: Warm up time for Malaria’s clim
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... ... management in hospitals, today announced it has completed a round of funding to ... LLC and its partners. Black Granite Capital is a growth equity firm focused ...
(Date:4/26/2017)... ... ... Journal of Oral Implantology – Tooth loss is not simply an ... complications with speech, eating, and overcompensation of mouth due to the deficiency. To combat ... number of tooth replacements increase, it is imperative to design an implant that will ...
(Date:4/26/2017)... ... April 26, 2017 , ... CareSet ... adoption of e-prescribing as measured in Part D Medicare data. The dataset, called ... pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") data ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be a result ... has helped many women become pregnant upon treating their diagnosis. , ... outpatient evaluations. We can provide the necessary information to diagnose and treat ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
Breaking Medicine Technology: